These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9232131)

  • 1. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe.
    Kharasch ED; Russell M; Garton K; Lentz G; Bowdle TA; Cox K
    Anesthesiology; 1997 Jul; 87(1):26-35. PubMed ID: 9232131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.
    Kharasch ED; Russell M; Mautz D; Thummel KE; Kunze KL; Bowdle A; Cox K
    Anesthesiology; 1997 Jul; 87(1):36-50. PubMed ID: 9232132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menstrual cycle variability in midazolam pharmacokinetics.
    Kharasch ED; Mautz D; Senn T; Lentz G; Cox K
    J Clin Pharmacol; 1999 Mar; 39(3):275-80. PubMed ID: 10073327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.
    Kharasch ED; Jubert C; Senn T; Bowdle TA; Thummel KE
    J Clin Pharmacol; 1999 Jul; 39(7):664-9. PubMed ID: 10392320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
    Ibrahim AE; Feldman J; Karim A; Kharasch ED
    Anesthesiology; 2003 Apr; 98(4):853-61. PubMed ID: 12657846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
    Phimmasone S; Kharasch ED
    Clin Pharmacol Ther; 2001 Dec; 70(6):505-17. PubMed ID: 11753266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
    Kharasch ED; Hoffer C; Walker A; Sheffels P
    Clin Pharmacol Ther; 2003 Mar; 73(3):199-208. PubMed ID: 12621385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
    Chaobal HN; Kharasch ED
    Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.
    Kharasch ED; Vangveravong S; Buck N; London A; Kim T; Blood J; Mach RH
    Clin Pharmacol Ther; 2011 Apr; 89(4):562-70. PubMed ID: 21346758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
    Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
    Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions.
    Baririan N; Horsmans Y; Desager JP; Verbeeck R; Vanbinst R; Wallemacq P; Van Obbergh L
    J Clin Pharmacol; 2005 Dec; 45(12):1434-41. PubMed ID: 16291719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
    Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?
    Kharasch ED; Thummel KE
    Anesth Analg; 1993 May; 76(5):1033-9. PubMed ID: 8484504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions.
    Labroo RB; Paine MF; Thummel KE; Kharasch ED
    Drug Metab Dispos; 1997 Sep; 25(9):1072-80. PubMed ID: 9311623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism.
    Labroo RB; Thummel KE; Kunze KL; Podoll T; Trager WF; Kharasch ED
    Drug Metab Dispos; 1995 Apr; 23(4):490-6. PubMed ID: 7600917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance.
    Yun CH; Wood M; Wood AJ; Guengerich FP
    Anesthesiology; 1992 Sep; 77(3):467-74. PubMed ID: 1519785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test.
    Krivoruk Y; Kinirons MT; Wood AJ; Wood M
    Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 1):608-14. PubMed ID: 7995002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
    Spracklin DK; Thummel KE; Kharasch ED
    Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.